Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Bristol ...

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Jun 05, 2022 9:13pm

130 Views

Post# 34732972

RE:Bristol ...

Bery interesting. Whats most surprising is that Immatics was able to secure these billions of dollars despite none of their pipeline IP being past Ph1. And most of the IP secured by Bristol is still in preclinical stages.

I really want to say ATE is lagging because of its size, poor captial market exposure (canada is very poor in that regard), and a meek CEO. But how can ATE not be farther ahead with its IP. The emerging therapeutic benefits of H2S is a breakthrough, and thats not hyperbole.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property